Sanofi's Billion-Dollar BFF!

Alright, folks, let’s dive into the world of biotech drama. Shares of Novavax (NVAX) have been on a tear, continuing their climb on Monday after the company dropped some major news last week. They announced a licensing deal with Sanofi, and the stock shot up 47.6%, closing at $13.11. That's the highest it's been since December 2022.

But wait, there's more! Novavax shares had already doubled last Friday on this news, and over the past three months, they’ve more than tripled. It’s like watching a rocket take off.

So what’s all the excitement about? Well, Novavax revealed that they’ve struck a deal with Sanofi to commercialize their Covid-19 vaccine worldwide. This deal is no small potatoes – it’s worth up to $1.4 billion, including milestone payments.

And here’s the kicker: Sanofi will get the exclusive license to use the Covid-19 vaccine in combination with its flu vaccine. Talk about a power couple in the vaccine world!

So, while the rest of us are trying to figure out how to get our foot in the market, Novavax is out here making billion-dollar deals and watching their stock soar. Who says biotech can’t be exciting?